Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women.

J Infect Dis · 2022 · PMC9200160 · PMID 34146100

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Additionally, a trend towards higher immune response was noted for the 120 RSVPreF3 dose level, but this did not reach statistical significance for all readouts, with the exception of day 8 ANCOVA results for anti-RSVPreF3 IgG antibodies.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.